DCDelivette Castor

Delivette Castor

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Delivette Castor has a total of 228 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Specification and Causal Pathway Diagramming of Implementation Strategies to Support Development of Access‐Enhancing Injectable HIV Treatment Programmes at Eight Diverse Health Clinics Across the United States

    by Kathrine Meyers, Nadia Nguyen, Charlie Ferrusi, Jason Zucker, Sarit A. Golub, Bryan A. Kutner, Mamta Karani, Cody A. Chastain, Marilyn Blasingame, Moya Brown‐Lopez, et al.

    Introduction: Long‐acting injectable antiretroviral therapy (LAI ART) represents a transformative development in HIV care because it may mitigate longstanding barriers that contribute to gaps in health outcomes. Providing LAI ART to people not consistently on HIV treatment or lacking treatment options requires intentional programme planning to overcome implementation barriers, without which only well‐resourced patients benefit, worsening health outcome gaps. The ALAI UP Project delivered clinic‐level implementation strategies to support eight clinics across Ending the HIV Epidemic jurisdictions to implement injectable cabotegravir and rilpivirine (iCAB/RPV). Methods: We specified seven implementation strategies and assessed their impact on clinic achievement of three key programme outcomes: (a) access to information about iCAB/RPV for all patients regardless of clinical eligibility; (b) access to iCAB/RPV regardless of healthcare coverage; and (c) access to iCAB/RPV for those who can clinically benefit the most, including patients who are unable to achieve durable viral suppression on oral ART for reasons other than cabotegravir or rilpivirine resistance. Implementation strategies were delivered from March 2023 through February 2025, and results are reported at the end of year 2 of the 3‐year project. We developed causal pathway diagrams (CPDs) for each strategy, identifying determinants, preconditions, moderators, mechanisms and outcomes. Results: ALAI UP strategies supported clinic progress towards all three outcomes: six clinics had partially or fully achieved access to information about iCAB/RPV for all patients, seven clinics had partially or fully achieved access to iCAB/RPV for patients regardless of healthcare coverage, and six clinics had provided access to iCAB/RPV for those who could benefit the most clinically. By developing CPDs for each strategy, we explicated how strategies operated across different clinical contexts. Through this process, we identified mechanisms of action that needed to be activated, moderators that impacted strategy strength and preconditions that needed to be in place for the strategy to function. These insights informed changes to strategies in the final year of the project. Conclusion: This work demonstrates that applying implementation science tools to service delivery projects can enhance precision and reproducibility of strategies, identify intervention points for improving strategies when mechanisms are not activated, and clarify hypothesized causal pathways testable in future hybrid effectiveness‐implementation trials.


  • Open Access

    Comfort with AI for HIV Prevention Among Cisgender Women in New York City

    by Harry Reyes Nieva, Max Flanagan, Simian Huang, Deborah A. Theodore, Amelie Foumena Nkodo, Melissa Parkinson, Sarah Hill, Megan McAndrew, Jorge Benitez, Henry Peralta, et al.

    Long-acting pre-exposure prophylaxis (PrEP) expands HIV prevention options for women. However, PrEP impact depends on addressing persistent gaps in awareness, access, and use. Artificial intelligence (AI) tools, including conversational agents, are being explored to advance PrEP uptake, but comfort with AI may influence their impact. Thus, we examined women’s comfort with AI and its association with PrEP awareness. We analyzed self-reported data from women aged ≥ 18 years in a cross-sectional survey conducted in New York City from August 2023 to August 2024. We performed descriptive analyses, applied latent class analysis to identify AI knowledge/comfort profiles, and estimated unadjusted and adjusted odds ratios to assess associations between profile membership and PrEP awareness. Among 306 respondents without a diagnosis of HIV who completed AI-related survey items, the median age was 36. Most women identified as Hispanic/Latina (60%) or Non-Hispanic Black (18%), had not completed college (53%), and spoke only English or were bilingual (81%). Latent class analysis identified four AI knowledge/comfort profiles that differed by PrEP awareness, race/ethnicity, borough, prior drug use, and technology utilization. Women with varied AI knowledge, broad AI discomfort, and comfort with clinicians maintaining privacy had lower odds of PrEP awareness (OR: 0.35, 95% CI: 0.16-0.75), but this association did not persist after statistical adjustment. PrEP awareness and AI knowledge were limited, yet many women expressed openness to AI-enabled tools when privacy was assured. AI-enabled HIV prevention tools should prioritize trust, transparency, confidentiality, and the lived contexts of the women they intend to serve.

  • Open Access

    Generative Artificial Intelligence in Medical Education and Participatory Research for Social Action: A Human and AI Comparative Analysis

    by Susana Juniu, Delivette Castor, Harry Reyes Nieva, Rita Charon, Silvia Amesty

    Participatory qualitative methods such as Photovoice are increasingly used to link research with social action. Recent advances in artificial intelligence (AI) may enhance data analysis, inference, and action planning within such participatory approaches. This study explored medical students’ perceptions of social justice using conventional Photovoice analysis and assessed the potential contribution of generative AI (genAI). Nine students joined a six-week seminar, “Exploring the Concept of Social Justice Using Photovoice.” An initial two-hour session covered ethics, the Photovoice framework, and photography techniques. Participants then captured images reflecting their views on social justice, wrote narratives, and engaged in guided group discussions. Human researchers and students conducted a three-stage Photovoice analysis: 1) selecting photographs, 2) contextualizing them with participant narratives, and 3) inductively coding themes. To explore how AI might support data analysis, the research team analyzed the same data with five generative tools, including Sonix, ChatGPT, and Copilot. AI-generated themes and visual representations were compared with human-derived results for congruence, depth, and suggested action steps. Conventional analysis identified five major themes: (1) Social Justice and Inequality, (2) Contradictions and the Costs of Justice, (3) Community and Collective Action, (4) Environment and Environmental Justice, and (5) Perception, Subjectivity, and Perspective. AI-assisted analysis yielded six unified themes that closely aligned with human findings. Traditional Photovoice images conveyed authentic, lived experiences and strong emotional meaning, providing a powerful foundation for advocacy. AI-generated images and thematic summaries offered efficiency, creativity, and reduced researcher bias, improving generalizability. However, they lacked the emotional depth and contextual nuance present in participant-created visuals.

  • Open Access

    Real-World Estimates of HIV Incidence From Sexual Health Clinic EMRs: Feasibility, Limitations, and Implications for Surveillance

    by Christa PhD Fischer Walker, Mu-Tien Lee, Pai Lien Chen, Kathleen PhD Ridgeway, Ariana Johnson, Suzanne Doblecki-Lewis, Delivette Castor, Jason Zucker, Daniela Quigee, Marina Mhs Rifkin, et al.

    Background: Timely and accurate estimates of HIV incidence are essential for program monitoring and planning clinical studies. Real-world evidence from electronic medical records (EMRs) in sexual health clinics may provide a pragmatic alternative to resource-intensive surveys and surveillance. Setting: We conducted a retrospective cohort study across 5 health centers in the United States, South Africa, and Thailand to assess the feasibility of estimating HIV incidence using EMR data. Methods: Clients aged 16–64 years assigned male at birth who reported ever having sex with someone assigned male at birth and had at least 1 HIV test between July 1, 2022, and December 31, 2023, were included. Deidentified data were extracted and subcohorts created considering 1 versus more than 1 HIV test during the study period. Incidence rates were calculated within the multiple-test (MT) cohort using person-time at risk; diagnosis proportions were calculated for all cohorts. Results: All sites met data quality thresholds for essential demographic and clinical variables. A total of 25,801 clients were included. Diagnosis proportions in single-test cohorts were higher (2.9%–12.6%) than in MT cohorts (0%–0.53%). Incidence rates among MT cohorts ranged from 0.22 to 0.72 per 100 person-years, substantially lower than expected, likely due to PrEP use and selection bias toward health-engaged clients. Conclusion: EMR-based HIV incidence estimation is feasible but limited by data variability and selection bias thus incidence estimates from MT cohorts may not reflect true community incidence. Diagnoses data may be used for incidence modeling where there is sufficient sample size.

  • Open Access

    A Digital Patient Decision Aid to Increase Sexually Transmitted Infection Testing in the Emergency Department: Protocol for a Pilot Randomized Controlled Trial of the STIckER (STI Check in the Emergency Room) Study

    by Jason Zucker, Delivette Castor, Marc A Probst, Talia Adler, Lisa-Pierre Tchoungui, Jaciara De Souza, Christina Franqui, Lauren Chernick

    Background: Rising rates of sexually transmitted infections (STIs) among adolescents and young adults are concerning. Emergency department (ED) visits offer a unique opportunity to increase STI testing. However, providers in the ED may not have the time or self-efficacy to screen patients, and patients may be unable to initiate discussion on their STI care needs. A patient decision aid may improve the effectiveness and efficiency of the ED encounter for STI testing. Objective: This study aims to pilot STI Check in the Emergency Room (STIckER) app, a shared decision-making aid for urinary, oral, and rectal gonorrhea and chlamydia testing among adolescents and young adults, and assess STIckER’s efficacy and implementation outcomes in an adult and pediatric ED. Methods: We are conducting a parallel-group, two-arm provider-randomized controlled pilot trial in the adult and pediatric EDs at an urban academic medical center. Fifty providers were randomized 1:1 to intervention (trained on STIckER) or control (standard of care). Adolescents and young adults aged 14‐24 years, English-speaking, and sexually active within the past 6 months are recruited during eligible shifts and assigned to the study arm of their provider. The standard of care comparator consists of usual provider-initiated STI discussions and testing without access to the decision aid; control participants receive a QR code directing them to a simple landing page encouraging them to ask their provider about STI testing. The planned enrollment target was 44 providers and 140 adolescent and young adult participants. Primary outcome is preliminary efficacy, defined as the proportion of adolescents and young adults receiving gonorrhea and chlamydia testing based on electronic medical record (EMR) review. Secondary outcomes include extragenital testing uptake, STI positivity rates, decisional conflict, and perceived level of shared decision-making. Implementation outcomes include feasibility, acceptability, appropriateness (using acceptability of intervention measure, intervention appropriateness measure, and feasibility of intervention measure), and provider self-efficacy. Data will be analyzed using descriptive statistics and regression models, with mixed-effects models applied if clustering by provider is detected. Exploratory analyses will examine differences by patient age, gender, and sexual identity, and provider characteristics. Results: Between September 2023 and July 2025, we completed recruitment of 44 providers and 139 adolescent and young adult participants across both adult and pediatric EDs. Enrollment targets were met, with high fidelity to intervention delivery and strong rates of survey completion by both patients and providers. Final data cleaning and analyses are underway, and primary results are expected to be available in late 2025. Conclusions: This pilot trial will provide critical data on the feasibility, acceptability, and preliminary efficacy of a digital SDM tool to increase STI testing in the ED. Findings will inform the design of a future multisite trial and the potential for scaling STIckER to support equitable, patient-centered STI screening across diverse clinical settings.


  • Correlates of asymptomatic sexually transmitted infections among marginalized women in the Dominican Republic

    by Michelle Chang, Delivette Castor, Craig J. Heck, Brian Hernandez, Angelina Gomes, Jason Zucker, Sara Wallach, Jonathan Gelfond, Mina Halpern, Yeycy Donastorg, et al.

    Background: Sexually transmitted infections (STIs) continue to cause morbidity among women in resource-constrained settings, where asymptomatic infections are often overlooked due to syndromic management protocols. We investigated correlates of asymptomatic STIs among women in the Dominican Republic (DR). Methods: We analyzed data collected from cisgender women in DR between 2015 and 2019. Classified groups included pregnant youth (PY), people with HIV (PWH), residents of bateyes (RB), and sex workers (SW). Nucleic acid amplification or rapid plasma reagin tests detected STIs (Chlamydia/Gonorrhoeae/Syphilis/Trichomonas). Asymptomatic comprised no self-reported vaginal discharge, dysuria, groin lymphadenopathy, and genital/anal pain/ulcers. Logistic regressions identified sociodemographic, clinical, and behavioral correlates. Results: Among 833 asymptomatic women (median age 29, IQR 19-37), 35% were PY, 27% PWH, 11% RB, and 27% SW. STI prevalence was 24%: most (61%) had Chlamydia and few (≤25%) had Gonorrhoea, Syphilis, or Trichomonas. Asymptomatic STI correlates included age ≤24 (Adjusted Odds Ratio [aOR] = 2.32, [1.65-3.28]), early (≤14) sexual debut (aOR = 1.56, [1.11-2.18]), greater mobility (aOR = 1.41, [1.01-1.97]), lack of regular doctor (aOR = 1.42, [1.01-1.99]), and drug use in last 6 months (aOR = 1.88, [1.07-3.26]). Conclusions: Correlates of asymptomatic STIs—age, sexual debut, mobility, healthcare access, and drug use—should inform targeted screening and prevention efforts where diagnostic testing is not widely available.

  • Open Access

    A cross‐sectional study evaluating the frequency of HIV drug resistance mutations among individuals diagnosed with HIV‐1 in tenofovir disoproxil fumarate‐based pre‐exposure prophylaxis rollout programmes in Kenya, Zimbabwe, Eswatini and South Africa

    by Urvi M. Parikh, Lauren D. Kudrick, Lisa Levy, Everline Bosek, Bhavna H. Chohan, Irene Mukui, Sarah Masyuko, Nonhlanhla Ndlovu, Imelda Mahaka, Owen Mugurungi, et al.

    Introduction: The ongoing rollout of oral tenofovir‐based pre‐exposure prophylaxis (PrEP) has the potential to reduce HIV‐1 incidence, but HIV drug resistance (HIVDR) in individuals who acquire HIV‐1 on PrEP could threaten the treatment effectiveness of overlapping antiretrovirals (tenofovir/emtricitabine), contribute to development of resistance, and undermine HIV control efforts. Accordingly, the Global Evaluation of Microbicide Sensitivity (GEMS) project was established to monitor HIVDR in PrEP rollout programmes in Southern and Eastern Africa. Methods: GEMS monitored resistance in >100,000 estimated persons who accessed PrEP through national programmes or implementation projects in Southern/Eastern Africa. Participants self‐reported demographics and PrEP adherence. HIV‐1 RNA and tenofovir‐diphosphate levels were measured in blood samples collected at the time of study enrolment from consenting participants diagnosed with HIV who had received PrEP. HIVDR mutations were detected by population genotyping. Results: Of 283 reported seroconversions on PrEP from December 2017 through September 2023, 255 (90%) individuals enrolled in GEMS, of which 81 (32%) were from Kenya, 77 (30%) from South Africa, 69 (27%) from Zimbabwe and 28 (11%) from Eswatini. Half (130; 51%) were 15–24 years of age at seroconversion, and three‐quarters (193; 76%) were female. Thirty‐four seroconversions occurred within 30 days of PrEP initiation. Tenofovir‐diphosphate levels were consistent with moderate to high levels (≥350 femtomoles per punch) in 53% (120 of 226) individuals with drug‐level data. Of 154 samples successfully genotyped, 34 (22%; 95% CI [16%, 30%]) had PrEP‐associated mutations; these included 27 samples with M184I/V, one sample with K65KR, and six samples with both K65R and M184I/V. Conclusions: The frequency of HIVDR mutations associated with tenofovir or emtricitabine among individuals diagnosed with HIV who had received PrEP (22%) exceeded background levels of transmitted nucleoside reverse transcriptase inhibitor resistance in Southern and Eastern Africa (≤5%) but people with PrEP‐associated mutations are likely to achieve virologic suppression with current first‐line antiretroviral therapy (ART). Improved screening for acute infection before initiating PrEP, surveillance of HIVDR with the introduction of new PrEP programmes and the monitoring of longer‐term ART outcomes in individuals who acquire HIV‐1 on PrEP will be essential to preserve antiretroviral options for both treatment and prevention.


  • Implementation of Doxy-PEP in a Diverse Sexual Health Program in Northern Manhattan: The Doxy-Care Study

    by Simian Huang, Caroline Carnevale, Natalie Neu, Joshua Klein, Daniela Quigee, Edward Perez, Lauren Burrell, Kathrine Meyers, Jacob McLean, Magdalena E. Sobieszczyk, et al.

    This prospective cohort study evaluated the real-world effectiveness of doxycycline postexposure prophylaxis use in reducing bacterial sexually transmitted infections (STIs) within a diverse urban sexual health program. Propensity-matched analyses showed significant STI reductions, particularly in rectal Chlamydia trachomatis infections, among early adopters. Uptake was disproportionately higher in non-Hispanic White individuals and those more engaged in care. Findings emphasize the need for targeted outreach to improve care engagement and equitable access to this STI prevention strategy. ( Am J Public Health. Published online ahead of print August 14, 2025:e1–e5. https://doi.org/10.2105/AJPH.2025.308209 )


  • Open Access

    Increased Depression and Anxiety Among Men and Transgender Women Receiving Care at a Sexual Health Clinic in New York City During COVID-19

    by Simian Huang, Jason Zucker, Delivette Castor, Caroline Carnevale, Elijah LaSota, Joshua Klein, Tae Yoon Kim, Daniela Quigee, Deborah Theodore, Peter Gordon, et al.

    Background: Clients seeking sexual health care often need concurrent mental healthcare services, which were disrupted during the COVID-19 pandemic. Using data from two studies conducted before and after the onset of COVID-19, we examined changes in self-reported depression and anxiety scores among clients in a sexual health clinic in New York City (NYC). Methods: We enrolled 144 participants pre-COVID-19 and 319 post-COVID-19 pandemic onset. Participants completed questionnaires assessing demographics, sexual behaviors, and mental health status. Primary mental outcomes included depression (Patient Health Questionnaire [PHQ-9]) and anxiety (Generalized Anxiety Disorder Scale [GAD-7]). We conducted descriptive analyses and used generalized linear mixed models (GLMM) to estimate predictors of mental health changes. Results: Cohorts were comparable by age, self-identified gender, race/ethnicity, income, HIV, and sexually transmitted infection assessment scores. Post-COVID-19 participants reported significantly higher mean PHQ-9 and GAD-7 scores compared with pre-COVID-19 participants (3.6 ± 4.2 vs 5.7 ± 5.3, P < .001; 3.9 ± 4.3 vs 5.1 ± 5.0; P = .019). Post-COVID-19 participants were also more likely to be uninsured or on Medicaid (2.7% vs 20%, 18% vs 30%, P < .001), and to report intimate partner violence victimization (24% vs 45%, P = .003). Adjusted GLMM showed post-COVID-19 was associated with a 1.55 (95% CI: .07, 3.03, P < .04) mean increase in PHQ-9 scores, but not GAD-7. Conclusions: Depression and anxiety scores increased after the onset of the COVID-19 pandemic in this NYC sexual health clinic sample. The sustained impact of the COVID-19 pandemic on depression calls for integrated, accessible mental health services within sexual health care settings.


  • Open Access

    Leveraging international stakeholders’ experiences with oral PrEP costs to accelerate implementation of the monthly dapivirine vaginal ring: A qualitative study

    by Craig J. Heck, Katharine Kripke, Anita Dam, Sergio Torres-Rueda, Fiammetta Bozzani, Chris Obermeyer, Kibret Yohannes, Justine Deacon, Kathrine Meyers, Daniela Quigee, et al.

    Costing and financing systematic implementation are recognized barriers to human immunodeficiency virus (HIV) prevention. In the absence of empiric implementation and economic data, perspectives from international stakeholders involved in developing and supporting daily oral pre-exposure prophylaxis (PrEP) policy, and programs can provide critical insights for developing costed plans to support and accelerate the rollout of novel long-acting PrEP (LA-PrEP) methods, such as the monthly dapivirine vaginal ring (PrEP ring). We interviewed stakeholders from purposively selected international organizations about anticipated PrEP-ring implementation costs, evidence gaps and key process steps for developing a costed rollout plan template (CRPT). We deductively analysed interviews. The 27 stakeholders (11 donors, 10 nongovernmental, 4 academic/research, 2 multilateral) identified 10 cost-related themes: 7 for planning and implementation and 3 for financing, costing and budgeting. Planning and implementation cost considerations included: (1) actionable target setting; (2) multilevel communication strategies for awareness-raising, demand creation, client-level adherence and choice counselling; (3) human resources, encompassing task shifting and integration into non-HIV services; (4) supply chain costs, including commodities, manufacturing diversification, packaging and forecasting; (5) laboratory infrastructure and monitoring; (6) updated health information systems and metrics to monitor and evaluate multiple methods integrated into HIV, non-HIV and de-medicalized delivery settings; and (7) technical assistance and knowledge management. Themes for financing, costing and budgeting comprised: (8) cost and budget analyses, such as cost–effectiveness; (9) economic evidence gaps on service integration; and (10) innovative or co-financing for sustainable and equitable allocation of limited financial resources to support accelerated PrEP-ring delivery. We organized these themes within the CRPT. The CRPT could expedite planning and enhance the pace and scale of optimized, systematic and sustainable delivery of PrEP methods. Further research is needed to evaluate use cases of the CRPT.